×

Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

AstraZeneca narrows review to four

Published on .

AstraZeneca has winnowed contenders to four in a $40 million media buying and planning review for Nexium, the successor to blockbuster heartburn drug Prilosec, an executive close to the situation said. The request for proposals on the account created a tempest among some media executives who felt it asked for too much proprietary information.

Copyright March 2000, Crain Communications Inc.

In this article:
Most Popular